365 related articles for article (PubMed ID: 31800075)
1. Pivotal clinical trials, meta-analyses and current guidelines in the treatment of hyperkalemia.
Bianchi S; Regolisti G
Nephrol Dial Transplant; 2019 Dec; 34(Suppl 3):iii51-iii61. PubMed ID: 31800075
[TBL] [Abstract][Full Text] [Related]
2. Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology.
Bianchi S; Aucella F; De Nicola L; Genovesi S; Paoletti E; Regolisti G
J Nephrol; 2019 Aug; 32(4):499-516. PubMed ID: 31119681
[TBL] [Abstract][Full Text] [Related]
3. New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors.
Tamargo J; Caballero R; Delpón E
Cardiovasc Drugs Ther; 2018 Feb; 32(1):99-119. PubMed ID: 29372448
[TBL] [Abstract][Full Text] [Related]
4. [Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS)].
Santoro A; Mandreoli M
G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786183
[TBL] [Abstract][Full Text] [Related]
5. Management of Hyperkalemia in Heart Failure.
Altay H; Çavuşoğlu Y; Çelik A; Demir Ş; Kılıçarslan B; Nalbantgil S; Temizhan A; Tokgöz B; Ural D; Yeşilbursa D; Yıldırımtürk Ö; Yılmaz MB
Turk Kardiyol Dern Ars; 2021 Oct; 49(Supp1):1-32. PubMed ID: 34738907
[TBL] [Abstract][Full Text] [Related]
6. Chronic hyperkalemia in non-dialysis CKD: controversial issues in nephrology practice.
De Nicola L; Di Lullo L; Paoletti E; Cupisti A; Bianchi S
J Nephrol; 2018 Oct; 31(5):653-664. PubMed ID: 29882199
[TBL] [Abstract][Full Text] [Related]
7. Potassium-Binding Agents to Facilitate Renin-Angiotensin-Aldosterone System Inhibitor Therapy.
Schaefer JA; Gales MA
Ann Pharmacother; 2016 Jun; 50(6):502-10. PubMed ID: 27009290
[TBL] [Abstract][Full Text] [Related]
8. Hyperkalemia in patients with chronic renal failure.
Seliger SL
Nephrol Dial Transplant; 2019 Dec; 34(Suppl 3):iii12-iii18. PubMed ID: 31800076
[TBL] [Abstract][Full Text] [Related]
9. Effect of patiromer on serum potassium in hyperkalemic patients with heart failure: Pooled analysis of 3 randomized trials.
Piña IL; Yuan J; Ackourey G; Ventura H
Prog Cardiovasc Dis; 2020; 63(5):656-661. PubMed ID: 33007353
[TBL] [Abstract][Full Text] [Related]
10. Role of Hyperkalemia in Heart Failure and the Therapeutic Use of Potassium Binders.
Sarwar CMS; Bhagat AA; Anker SD; Butler J
Handb Exp Pharmacol; 2017; 243():537-560. PubMed ID: 28382468
[TBL] [Abstract][Full Text] [Related]
11. Advances in treatment of hyperkalemia in chronic kidney disease.
Sarafidis PA; Georgianos PI; Bakris GL
Expert Opin Pharmacother; 2015; 16(14):2205-15. PubMed ID: 26330193
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics.
Weir MR; Mayo MR; Garza D; Arthur SA; Berman L; Bushinsky D; Wilson DJ; Epstein M
J Hypertens; 2017 May; 35 Suppl 1(Suppl 1):S57-S63. PubMed ID: 28129247
[TBL] [Abstract][Full Text] [Related]
13. Potassium Binders for Hyperkalemia in Chronic Kidney Disease-Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis.
Palmer BF
Mayo Clin Proc; 2020 Feb; 95(2):339-354. PubMed ID: 31668450
[TBL] [Abstract][Full Text] [Related]
14. Hyperkalemia in heart failure: current treatment and new therapeutic perspectives.
Minà C; Ajello L; Gesaro GD; Falletta C; Clemenza F
Rev Cardiovasc Med; 2020 Jun; 21(2):241-252. PubMed ID: 32706212
[TBL] [Abstract][Full Text] [Related]
15. Potassium-lowering agents for the treatment of nonemergent hyperkalemia: pharmacology, dosing and comparative efficacy.
Bridgeman MB; Shah M; Foote E
Nephrol Dial Transplant; 2019 Dec; 34(Suppl 3):iii45-iii50. PubMed ID: 31800078
[TBL] [Abstract][Full Text] [Related]
16. [Effect of hyperkalemia and RAASi nonadherence on patients affected by heart failure or chronic kidney disease].
Degli Esposti L; Perrone V; Giacomini E; Sangiorgi D; Alessandrini D; Santoro A
G Ital Nefrol; 2019 Sep; 36(5):. PubMed ID: 31580544
[TBL] [Abstract][Full Text] [Related]
17. Current Management of Hyperkalemia in Non-Dialysis CKD: Longitudinal Study of Patients Receiving Stable Nephrology Care.
Borrelli S; De Nicola L; Minutolo R; Conte G; Chiodini P; Cupisti A; Santoro D; Calabrese V; Giannese D; Garofalo C; Provenzano M; Bellizzi V; Apicella L; Piccoli GB; Torreggiani M; Di Iorio BR
Nutrients; 2021 Mar; 13(3):. PubMed ID: 33804015
[TBL] [Abstract][Full Text] [Related]
18. The tolerability and safety profile of patiromer: a novel polymer-based potassium binder for the treatment of hyperkalemia.
Pitt B; Garza D
Expert Opin Drug Saf; 2018 May; 17(5):525-535. PubMed ID: 29667438
[TBL] [Abstract][Full Text] [Related]
19. Association of Changes in Creatinine and Potassium Levels After Initiation of Renin Angiotensin Aldosterone System Inhibitors With Emergency Department Visits, Hospitalizations, and Mortality in Individuals With Chronic Kidney Disease.
Garlo KG; Bates DW; Seger DL; Fiskio JM; Charytan DM
JAMA Netw Open; 2018 Nov; 1(7):e183874. PubMed ID: 30646338
[TBL] [Abstract][Full Text] [Related]
20. New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval.
Zannad F; Rossignol P; Stough WG; Epstein M; Alonso Garcia Mde L; Bakris GL; Butler J; Kosiborod M; Berman L; Mebazaa A; Rasmussen HS; Ruilope LM; Stockbridge N; Thompson A; Wittes J; Pitt B
Int J Cardiol; 2016 Aug; 216():46-51. PubMed ID: 27140336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
